Security record · archived quarter
CELC
Celcuity Inc. · Healthcare · Biotechnology
2Tracked holders
-1Δ holders
1.49MShares held
$118.65MReported value
+0New positions
−1Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | -1 | 1.49M | $118.65M | n/a | −1 |
| Q2 2026 | 98 | +5 | 24.26M | $2.54B | +12 | −7 |
| Q1 2026 | 96 | +13 | 18.05M | $2.05B | +17 | −5 |
| Q4 2025 | 83 | -2 | 17.89M | $1.79B | +1 | −2 |
| Q3 2025 | 16 | +3 | 9.73M | $480.43M | +3 | n/a |
| Q2 2025 | 10 | 0 | 5.98M | $79.79M | +1 | −1 |
| Q1 2025 | 7 | 0 | 2.39M | $24.13M | n/a | n/a |
| Q4 2024 | 7 | -1 | 2.58M | $33.71M | +1 | −2 |
| Q3 2024 | 7 | -1 | 1.77M | $26.33M | +1 | −2 |
| Q2 2024 | 8 | n/a | 1.21M | $19.80M | n/a | n/a |
Who holds it · Q3 2026
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Assenagon Asset Management S.A. | 1.48M | +292.9% | $117.58M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 2 | Wealth Enhancement Advisory… | 15.79K | -0.6% | $1.07M | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| TD Waterhouse Canada Inc. | $7,940 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 275 holders, 48.99M shares, $5.37B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Aug 11
SC 13G: BANK OF AMERICA CORP /DE/
Jul 16
SC 13G: BAKER BROS. ADVISORS LP
Jul 16
SC 13D/A: BAKER BROS. ADVISORS LP
10.0% of class · View original SEC filing ↗
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q3 2026 ·
Methodology ·
Get this via the API